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Abstract: Skin and soft tissue infections (SSTIs) are the second most common infection 
encountered in hospitals. Management decisions have become increasingly complex due to the 
prevalence of resistant pathogens, the wide array of licensed antimicrobials and the availability 
of potent oral agents and of out-patient parenteral antibiotic therapy. Daptomycin is one of the 
newer therapeutic agents licensed for complex SSTI management. Rapid cidality, good soft 
tissue penetration, once daily IV bolus administration and activity against resistant Gram-
positive infections make daptomycin an attractive option both in hospitalized and community 
treated patients. A comprehensive review of the evidence for and experience with daptomycin 
and its use in SSTIs is presented.
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Introduction
Daptomycin is the first cyclic lipopeptide and many of its qualities favor its use in 
complicated skin and soft tissue infections (cSSTIs). It was approved at a dose of 
4 mg/kg for this indication by the Food and Drug Administration (FDA) in the United 
States in 2003 and subsequently in Europe in 2006.1 Daptomycin also has approval 
for use in Staphylococcus aureus bacteremia and right-sided endocarditis at a dose of 
6 mg/kg. Beiras-Fernandez et al have provided a fuller review of daptomycin’s other 
clinical applications previously in this journal.2 Herein we review published data and 
experience with daptomycin in cSSTI.
Skin and soft tissue infections: clinical features  
and microbiology
Skin and soft tissue infections (SSTIs) can be defined as a suppurative microbial 
invasion of the epidermis and subcutaneous tissues that induce either a local or sys-
temic host response. SSTIs are characterized by induration, erythema, warmth and 
pain or tenderness3 and range from mild self-limiting furunculosis to life-threatening 
necrotizing fasciitis.
Complicated SSTIs (cSSTIs) are those either involving deep soft tissue, or requiring 
significant surgical intervention (such as infected ulcers, burns, and major abscesses), 
or those in which a significant underlying disease state complicates the response to 
treatment (for example diabetes mellitus, obesity, immune deficiency, or underlying 
venous or arterial insufficiency).4 Various severity stratifications have been developed 
including one by Eron et al,3 forming the basis of the UK and CREST guidelines, Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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and one by Ki and Rotstein in Canada.5 Such classifications 
are designed to alert the clinician to the level of care required 
and the need for ancillary therapies, as well as guiding the 
choice and route of administration of antibiotic therapy, 
but they remain to be validated. A recent retrospectively 
validated severity classification, using an adaptation of the 
Eron classification, stratifies patients with SSTI based on 
the presence of the systemic inflammatory response and the 
physiological standardized early warning score (SEWS) and 
suggests that the presence of co-morbidities is less significant 
in predicting outcome.6
The main etiological agents implicated in SSTIs are 
the Gram-positive organisms, Staphylococcus aureus 
(S. aureus), and the beta-hemolytic streptococci (Groups 
A, B, C and G). Methicillin-resistant S. aureus (MRSA) 
infections have risen in prominence over the last 20 years, 
comprising 59% of S. aureus isolates in a recent study 
in the USA7 and .10% of isolates in 19 out of the 28 
countries in the 2009 European Antimicrobial Resistance 
Survey.8 The 2 distinct epidemiological forms of MRSA, 
community acquired (CaMRSA) and healthcare associated 
(HaMRSA) have quite different clinical features, largely 
as a consequence of the presence of the Panton Valentine 
leucocidin toxin in CaMRSA (Table 1). Increasingly how-
ever, considerable clinical overlap has been observed as 
HaMRSA presents in the community and CaMRSA emerges 
and spreads in healthcare facilities. Local prevalence of 
MRSA is not only important from the infection control 
perspective but also the empirical choice of antibiotic for 
SSTI. UK MRSA guidelines state that if the local prevalence 
of MRSA exceeds 10% of S. aureus isolates, then empiri-
cal treatment of a suspected S. aureus infection (including 
SSTI) should include anti-MRSA activity.9
Antibiotic therapy for SSTI
Beta lactam antibiotics, in particular the penicillinase stable 
penicillins (flucloxacillin and cloxacillin) remain the main-
stay of treatment for suspected streptococcal and methicillin-
sensitive S. aureus infections. Combination therapy with 
flucloxacillin and benzyl penicillin, although still widely 
practiced, is outdated.10 In proven penicillin-sensitive infec-
tion, rationalization to benzyl penicillin remains appropriate. 
Addition of intravenous clindamycin in rapidly progressive 
infections is advised as beta lactam antibiotics may be less 
effective in the static growth phase as characterized by 
severe streptococcal infections. Additional Gram-negative 
cover may also be considered in severe hospital-associated 
cSSTIs.
Vancomycin, discovered more than 50 years ago, has 
been the mainstay of therapy in MRSA infections and for 
patients intolerant or allergic to the beta lactams.   Emerging 
data however suggest slower bacterial clearance and poorer 
clinical response in vancomycin-treated patients with 
methicillin-sensitive S. aureus (MSSA infection) compared 
to those treated with beta lactam agents.11 There are also 
increasing reports of intermediate vancomycin resistance by 
a variety of mechanisms.12 These factors, as well as concerns 
over potential vancomycin toxicity, have led to the develop-
ment of new anti-MRSA agents such as the oxalodindiones 
(linezolid), new beta-lactam agents (eg, ceftobiprole and cef-
taroline), new glycopeptides (dalbavancin and telavancin), the 
glycylcycline tigecycline and daptomycin. In addition there 
is renewed interest in older agents with anti-MRSA activ-
ity such as trimethoprim-sulfamethoxozole, clindamycin, 
sodium fucidate and tetracyclines, particularly in the context 
of CaMRSA. Of all these agents, linezolid and daptomycin 
have the largest evidence base supporting their efficacy and 
Table 1 Clinical and epidemiological differences between healthcare associated and community acquired MRSA infection
Healthcare associated 
MRSA infection
Community acquired 
MRSA infection
Prior hospitalizations/healthcare contact Yes No
History of prior antibiotic use Yes No
Chronic medical conditions, eg, diabetes 
mellitus, chronic kidney disease, vascular 
disease, decubitus ulcers
Yes No
Contact sport, or living/working in crowded 
and/or unsanitary conditions
No Yes
Men who have sex with men No Yes
Surgical site infections Yes No
Furuncles, boils and abscesses (recurrent) Not typically Typical
Severe necrotizing pneumonia No Yes
Panton valentine leucocidin toxin producing No Yes
Antimicrobial resistance Multidrug resistance Beta-lactam resistance aloneInfection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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safety in cSSTIs.13–16 Linezolid is highly   effective in SSTI 
therapy and has an advantage over other agents used in severe 
SSTI in that it has an oral formulation which facilitates early 
IV to oral switch and the potential for earlier hospital dis-
charge. Myelo- and mitochondrial toxicity, along with various 
drug interactions can reduce its utility, particularly when 
longer term therapy is required.17 Evidence for daptomycin 
use in SSTI, is discussed below.
Pharmacology of daptomycin
Pharmacodynamics
Daptomycin demonstrates rapid, concentration-dependent, 
bactericidal activity in vitro against susceptible and resistant 
Gram-positive cocci, including MRSA, glycopeptide- and 
linezolid-resistant S. aureus and vancomycin-resistant 
enterococcal species.18,19 It has a novel mode of action, induc-
ing cell death by calcium-dependent efflux of potassium 
following insertion of its lipophilic tail into the cell 
membrane.20 It shows a strong post-antibiotic effect against 
S. aureus, and in contrast to the beta lactam antibiotics 
maintains its activity against bacteria in stationary-phase 
growth.21
Daptomycin has been shown, in experimentally induced 
blister fluid in healthy volunteers, to have 68% dermal pen-
etration as measured by the ratio under the concentration-time 
curve over 24 hours.22 A case report describing daptomycin 
concentrations in synovial fluid shows similar levels of 
tissue penetration, with synovial daptomycin levels found 
to be 70% of those in the serum.23 Furthermore, a recent 
pharmacokinetic study of daptomycin 6 mg/kg in 10 patients 
with diabetic foot infection found free plasma concentrations 
equilibrating completely with soft tissue and metatarsal bone 
within 3 hours of the start of a 30 minute infusion, and this 
was not affected by inflammation.24
Daptomycin has no Gram-negative activity, and although 
there are some data showing in vitro activity against anaero-
bic Gram-positive organisms, this is difficult to assess due to 
lack of clinical data to support breakpoints.21 This highlights 
the need to consider additional antimicrobials when used for 
cSSTIs where suspicion of mixed infection is high, eg, in 
necrotic diabetic foot infections.
Daptomycin is highly protein bound (91%) and renally 
excreted. Normally given as a once daily bolus according 
to patient weight, it is dosed 48 hourly in patients with a 
creatinine clearance (CrCl) of ,30 mL/minute25 or   following 
dialysis.
Elevation in creatinine phosphokinase (CPK) and 
associated myopathy was frequently seen in early clinical 
studies when the daptomycin was administered via multiple 
daily injections. CPK elevation is rare in short term treated 
patients receiving 4 mg/kg.15,26 In the Fowler et al study of 
daptomycin use in bacteremia and endocarditis where it was 
used at a dose of 6 mg/kg/day, CPK elevations were seen 
in 6.7% of the daptomycin treated group, but led to discon-
tinuation of therapy in only 3 of the 120 patients (2.5%).27 
CPK levels should be monitored weekly, or more often in 
those with myalgia, or concomitant renal failure, or when 
drugs associated with elevated CPK levels and myopathy 
are co-administered.21 The FDA has also recently published 
a drug safety communication highlighting the potential 
for developing eosinophilic pneumonia during treatment 
with   daptomycin.28 The pharmacokinetics, safety and effi-
cacy in children have not been established and are under 
  investigation.29 It is pregnancy category B.
Daptomycin’s potential for true pharmacokinetic interac-
tions is low as it does not undergo significant metabolism 
in vivo, and does not induce or inhibit the cytochrome P450 
pathway.1 Although not a drug–drug interaction or side-
effect per se, daptomycin may cause a spurious rise in the 
measured prothrombin time due to an interaction with some 
test reagents. This can lead to difficulties in therapeutic 
monitoring for warfarin. The effect can be minimized by 
drawing the international normalized ratio (INR) blood 
sample just before the daptomycin is given30,31 or by using 
alternative reagents.
Review of comparative clinical studies 
assessing daptomycin use for cSSTIs 
(Tables 2 and 3)
The initial data supporting the use of Daptomycin 
4 mg/kg/day in cSSTIs came from two Phase III randomized, 
investigator blinded, controlled clinical trials, comparing it 
with vancomycin or a semi-synthetic penicillin. The study 
population was adults (mean age 51) with cSSTIs who were 
judged to require hospitalization and parenteral antibiotics 
for $96 hours.15 In total, 1092 patients were included across 
139 sites in the USA, Europe, South Africa, Australia and 
Israel between 1999 and 2001. Exclusion criteria included 
minor infections, third-degree burns, known bacteremia at 
enrolment, concomitant infection at another site (osteomy-
elitis, septic arthritis, or endocarditis) or a requirement for 
curative surgery (eg, amputation). The primary efficacy end 
point was the non-inferiority of daptomycin to the compara-
tor in clinical success (resolution of signs and symptoms 
such that no further antibiotic therapy was required) in the 
clinically evaluable and intent-to-treat (ITT) populations at Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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Table 3 Summary of outcomes in published comparative studies of daptomycin in patients with cSSTIs
Study Median duration of 
therapy with study 
drug (days)
Clinical success for CE 
population, n/N (%)
Clinical success in 
patients with MRSA 
infections
Patients with treatment- 
related AEs, n/N (%)
D C D C D C D C
Arbeit15 Not known Not known 372/446 (83) 384/456 (84) 21/28 (75) 25/36 (69) 94/534 (18) 119/558 (21)
Phase III multicenter RCTs
Davis36 4 7 41/53 (77) 89/212 (42) 15/15 (100) 30/30 (100) 0/56 (0) 0/212 (0)
Prospective open-label, vs 
historical controls
Katz35 4a 8a 32/39 (82) 37/39 (95) 24/31 (77) 27/28 (96) 20/48 (42) 11/48 (23)
Multicenter RCT
Pertel34 6.1* 6.2* 47/47 (100) 46/47 (98) NR NR 3/50 (6) 1/51 (2)
Multicenter RCT
Gollnick33 8∼ 7∼ 53/58 (91.4) 41/47 (87.2) NR NR 55/97 (56.7) 51/92 (55.4)
Phase IIIb Multicenter RCT
Notes: aStudy designed to assess outcomes in a group of patients receiving high-dose daptomycin for 4 days versus comparator for #14 days; *Mean length of Iv therapy ∼Iv 
therapy was for at least 4 days.
Abbreviations: Ce, clinically evaluable; MRSA, Methicillin-resistant Staphylococcus aureus; Ae, adverse events; NR, not recorded; NA, not applicable.
Table 2 Characteristics of Daptomycin comparative SSTI studies
Study Design Patient characteristics Daptomycin (dose, 
treatment duration)
Comparator (type, dose, 
treatment duration)
Arbeit15 2 multicenter 
evaluator-blinded RCTs
N = 1092, adults with 
Gram-positive cSSTIs requiring 
hospitalization and Iv antibiotics 
for $4 days
4 mg/kg Iv once daily 
for 7–14 days
vancomycin Iv 1 g bd for 
7–14 days or penicillinase-
resistant penicillin Iv 4–12 g 
Iv q.d in equally divided doses
Davis36 Prospective open label N = 56, hospitalized adults, 
cSSTIs at risk of MRSA, 
prospectively enroled; 
212 historical controls 
treated with vancomycin
4 mg/kg Iv once daily 
for 3–14 days
vancomycin Iv dosed 
according to trough 
concentrations $3 days 
switched to semi-synthetic 
penicillin in absence of MRSA 
infection
Katz35 Multicenter, semi-single 
blinded RCT
N = 100, adults with cSSTIs 
at risk of MRSA, requiring 
Iv antibiotics
10 mg/kg Iv once daily 
for 4 days
vancomycin Iv 1 g bd or 
semi-synthetic penicillin Iv 
2 g q4h for #14 days
Pertel34 Multicenter, 
evaluator-blinded RCT
N = 103, adults with SSTI 
requiring hospitalization/iv 
antibiotics
4 mg/kg Iv once daily 
for #14 days
vancomycin Iv standard doses 
for 7–14 days
Gollnick33 Phase IIIb multicenter RCT N = 189, adults with cSSTI 
requiring hospitalization
4 mg/kg once daily 
for 4–14 days
Iv vancomycin or Teicoplanin 
for 4–14 days
Abbreviations: Ce, clinically evaluable; ITT, intent-to-treat (all patients who received one or more doses of study medication); RCT, randomized controlled trial; Iv, 
intravenous; cSSTI, complicated skin and soft tissue infections.
a test of cure (TOC) visit (6–20 days after the last dose of 
therapy).
Baseline characteristics were similar with wound infec-
tion comprising 44% of underlying diagnoses, 24% with 
major abscesses, 12% infected diabetic ulcers and 37% with 
a systemic inflammatory response (SIRS). Over 80% of 
patients had the infecting organism identified, 70% of which 
were S. aureus (10% were MRSA).
The two trials, both individually and collectively, met 
the predefined statistical criteria for non-inferiority of 
  daptomycin against comparator therapy (,10% difference 
in the upper limit of the 95% confidence interval between 
the groups’ success rates). Success in the clinically evaluable 
and microbiologically evaluable populations was compa-
rable, and no organism-specific difference was observed 
in response to treatment. In particular daptomycin was 
as effective as both vancomycin against MRSA (clinical 
success in 75% of those in the daptomycin arm, 69% in 
the comparator arm), and penicillinase-resistant penicillin 
against methicillin-sensitive S. aureus (MSSA) (clinical Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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success in 86% of those in the daptomycin arm, 87% in the 
comparator arm).15
This study was not designed to assess differences in 
duration of parenteral therapy between groups, however a 
post hoc analysis of the study population that received only 
intravenous therapy (89.8% of the total), found that 63% 
of the daptomycin-treated group required only 4–7 days 
of therapy compared with 33% of the comparator arm 
(P , 0.0001). A further analysis of a subset of the South 
African enrolled patients with # one co-morbidity showed 
that the median duration of therapy was shorter in the 
daptomycin group (7 versus 8 days for the comparator group, 
P , 0.0001).32
A subsequent Phase IIIb multi-center randomized 
assessor-blinded study33 compared the efficacy and safety 
of daptomycin versus vancomycin or teicoplanin for the 
treatment of cSSTIs. The primary objective was to compare 
daptomycin to its comparator at day 7–14 for clinical suc-
cess (complete resolution of clinical signs and symptoms or 
improvement requiring no additional therapy). Patients with 
cSSTIs were included if they were expected to receive at 
least 4 days of IV therapy before step down to oral therapy, if 
needed, and were randomized (1:1) and stratified by age ($65 
years) and systemic inflammatory response syndrome (SIRS) 
to receive either daptomycin (4 mg/kg IV once daily [OD]) 
or a glycopeptide (vancomycin 1 g IV BD or teicoplanin 
400 mg IV OD). 189 patients (97 in the daptomycin arm, 92 
in the comparator) from 29 centers across Europe received 
treatment. Baseline demographics were similar, with 1/3 of 
patients $65 years old and SIRS present in 58.8% in the 
daptomycin arm and 56.5% in the pooled comparator. In this 
study the median time to switch to oral therapy or end therapy 
was the same in both groups (8 days), and success rates in the 
clinically evaluable population were similarly high in both 
groups (91.4% for daptomycin and 87.2% for the pooled 
comparator) although in elderly patients there was a trend 
to a higher clinical success rate with daptomycin than with 
the pooled comparator (88.9% versus 76.5%,   respectively, 
(Confidence interval [CI] -22.4, 45.1).33
A summary of the outcomes from these 3 studies along 
with the other main comparative studies discussed in this 
review are presented in Table 3.
Meta-analysis of daptomycin 
therapy for cSSTIs
Three randomized controlled trials (RCTs) and 1 prospective 
comparative study (included in Tables 3 and 4) were included 
in a recent meta-analysis comparing the effectiveness of 
daptomycin with other agents in the treatment of SSTIs.16 
Three studies only included patients with cSSTIs whilst 
one included non-complicated SSTIs.34 Vancomycin and 
semi-synthetic penicillins were the comparator agents used. 
Short-term high-dose daptomycin therapy (10 mg/kg/day for 
4 days) was evaluated in one study.35 In total 1557 patients 
were evaluated (688 in the daptomycin group). No statisti-
cally significant difference in clinical success or toxicity 
in the clinically evaluable or ITT populations was noted. 
No firm conclusions on the comparative efficacy of dap-
tomycin verses vancomycin in MRSA infection could be 
drawn due to significant differences between the studies in 
the proportion of patients infected with MRSA.
Two studies have specifically examined duration of IV 
therapy as an outcome but results have been inconclusive: In 
a nonrandomized study utilising retrospective vancomycin 
Table 4 Characteristics of SSTI patient population included in CORe 2004, 2005 and eU-CORe 2006–‘08
Characteristic CORE 2004 SSTI subgroup40 
(n = 522)%
CORE 2005 SSTI subgroup41,42 
(n = 486)%
EU-CORE 2006–200839,44 
(n = 484)%
Age . 66∼ 24 21 53
CrCl , 30 mL/minute 26 12 9
Diabetes 27 30 41
cSSTIs 64 70 100
Bacteremia 3 5 NR
Prior antibiotic therapy 67 74 62
Prior vancomycin Not reported 49 22*
MRSA# 63 52 33 
enterococcal sp 19 Not reported 10
vRe** 8 Not reported 3
Notes: ∼Age $ 65 in eU-CORe group; NR, not recorded; *Percent of all eU-CORe data from this time period ie, includes the non-SSTI patients; #Percent of all positive 
isolates that were MRSA positive; **Including both vancomycin resistant Enterococcus faecium and faecalis.
Abbreviations: vRe, vancomycin resistant enterococcus; MRSA, methicillin resistant Staphylococcus aureus; SSTI, skin and soft tissue infections; cSSTI, complicated skin 
and soft tissue infections; CrCl, creatinine clearance; CORe, Cubicin Outcomes Registry and experience program; eU-CORe,  european Cubicin Outcomes Registry and 
experience program.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
120
White and Seaton
treated controls,36 median duration of time of IV therapy, 
as well as time to clinical cure and length of stay was less 
(4 days [range 2–13] versus 7–8 days [range 3–19]) in the 
daptomycin arm. Notably a higher proportion of patients with 
MRSA received daptomycin (Table 4). In a setting of high 
MRSA prevalence, an unusual study was employed whereby 
96 patients were randomized to 4 days of high dose dapto-
mycin (10 mg/kg/day) or 8 days of intravenous vancomycin 
with the option to switch to a semi-synthetic penicillin in 
sensitive isolates.35 Both arms could switch to oral therapy 
following clinical improvement. The study was not statistically 
powered to detect differences between treatment groups, but 
a trend towards better outcome in the comparator group with 
longer therapy was observed.   Differences were more pro-
nounced in the MRSA subgroup, which itself has previously 
been identified as an independent predictor of longer hospital 
stays and poorer clinical outcome irrespective of therapy.37
A further meta-analysis has looked at the comparative 
effectiveness of antibiotics for the treatment of MRSA 
complicated skin and soft tissue infections using a Bayesian 
statistical approach which enables combining of evidence 
to handle indirect comparisons.38 It compared treatment of 
cSSTI by vancomycin, linezolid, daptomycin, tigecycline 
and the novel glycopeptides dalbavancin and telavancin. 
  Following a literature search which initially identified 1632 
papers, it included 13 studies within which they could 
specifically look at the subset of patients with confirmed 
MRSA-related cSSTIs. Of these however it only included one 
paper on daptomycin,15 which only included 28 patients with 
MRSA infection. No difference in effect between daptomycin 
(success rate of 78.1%; 95% Bayesian confidence interval 
[CrI95%]: 54.6%–93.2%) and vancomycin (pooled success rate 
of 74.7%; CrI95%: 64.1%–83.5%) was demonstrated.
Review of non-comparative studies 
of daptomycin use in cSSTIs
There is now increasing experience with daptomycin world-
wide, with over an estimated 1,000,000 treated patients by 
mid-2010.39 Clinical experience with daptomycin has been 
captured within the Cubist-sponsored Cubicin Outcomes 
Registry and Experience (CORE) programme: a multi-center 
retrospective observational programme based in the United 
States, and now by the Novartis Pharma AG-sponsored 
European registry (EU-CORE). Data have been collected 
on patients who have received daptomycin outside the trial 
setting, providing ‘real-life’ experience. The data produced 
should be interpreted with care due to their retrospective, 
observational nature and potential inclusion bias.
Patient characteristics and outcomes for those with 
cSSTIs from CORE 200440 and 2005,41–43 as well as from 
EU-CORE analysis for January 2006 to August 200839,44 are 
presented here (Tables 4 and 5).
MRSA infections make up the majority of positive 
isolates in the earlier registry groups (63% in 2004, 52% in 
2005), but a smaller proportion of the European group per-
haps reflecting recent decline in MRSA in some participating 
European nations. Nonetheless, MRSA still accounted for 
over 50% of all S. aureus isolates. The high rate of prior 
antibiotic use has been notable across all registry groups, 
with glycopeptides and in particular vancomycin being the 
most common preceding antibiotic. Switch to daptomycin 
was most commonly observed following treatment failure. 
The EU-CORE data show similarly low failure rates whether 
daptomycin was prescribed as first- or second-line therapy 
(6% versus 8% respectively)39 suggesting perhaps that prior 
vancomycin therapy does not increase the risk of daptomycin 
failure.
For patients treated for SSTI, a median dose of 4 mg/kg 
was observed most frequently with a higher mean dose used in 
cSSTIs compared with uSSTIs (4.5 mg/kg versus 4.2 mg/kg 
in 2004 (P , 0.001) and 4.7 mg/kg versus 4.4 mg/kg in 
2005). In the most recent data from EU-CORE a significant 
proportion of those with cSSTIs (43%) received $6 mg/kg, 
possibly indicating the complexity of infections treated, and 
perhaps increasing confidence in daptomycin’s safety and 
tolerability at these doses.
Table 5 Clinical outcomes and treatment characteristics of patients treated with daptomycin for cSSTIs in CORe 2004, 2005, 2007 
and eU-CORe 2006–‘08
Study Patient group Success rate in 
CE patients (%)
Success rate in 
MRSA infections (%)
Mean dose 
mg/kg (range)
Median duration 
of therapy (days)
CORe 200440 cSSTIs (n = 334) 96 136/144 (97) 4.5 (2.3–12) 14
CORe 200541,42 cSSTIs (n = 333) 93 Not known 4.7 (2–10) 13
eU-CORe 2006–200839,44 cSSTIs (484) 84 152/187 (81.5)a Not knownb 10
Note: aTotal MRSA population including non-cSSTIs; bMean/median dose not recorded, but 44% of patients received 4 mg/kg, and 43% received $6 mg/kg.
Abbreviations: cSSTI, complicated skin and soft tissue infection; Ce, clinically evaluable; MRSA, methicillin resistant Staphylococcus aureus; CORe, Cubicin Outcomes 
Registry and experience program; eU-CORe, european Cubicin Outcomes Registry and experience program.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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Overall clinical success was judged by local investigators 
as ‘cured’ where no further antibiotic therapy was required, 
and ‘improved’ where there was clinical improvement but 
further therapy was required following daptomycin.45 Overall 
success was .90% in both the CORE 2004 and 2005 stud-
ies, and .80% in the EU-CORE registry (Table 5). High 
success rates were maintained in patients with confirmed 
MRSA infections. The median time to clinical response, as 
evidenced by signs and symptoms was 4 days (range 1–32) 
for patients with cSSTIs (2004 registry).
A multivariate analysis of the CORE 2005 cohort 
determined that sepsis, ICU stay and creatinine clear-
ance ,30 mL/minute were significantly associated with 
clinical failure.43 However, a subsequent stepwise multivari-
ate regression analysis of a larger data set of patients with 
S. aureus infections from CORE 2005 to 2007 found that the 
only independent predictors of clinical failure with daptomy-
cin therapy were the presence of endocarditis, bacteremia, 
severe renal dysfunction (CrCl , 30 mL/minute) and dia-
betes   mellitus.46 Each of these factors have been found to be 
associated with increased infection-related complications and 
mortality in previous studies.27,47 This analysis also suggested 
that prior treatment with other antibiotics, including vanco-
mycin, did not independently influence treatment outcomes 
with daptomycin, even if the reason for using daptomycin 
was prior treatment failure.46
Daptomycin in specific cSSTIs
As previously noted cSSTIs comprise a diverse group of 
infections with similar etiology but varying environmental 
and host factors. Differing infection types may present 
diverse therapeutic challenges. Some of these have been 
investigated in sub groups of prospective clinical trials whilst 
others have been retrospectively evaluated in   post-marketing 
studies.
Surgical site infections (SSI)
In the CORE 2007 population,48 118 of the 962 patients 
had SSI. Of these 104 (11%) met the criteria for an efficacy 
analysis. Positive microbiology was found in 73% and the 
majority were S. aureus (59%) with MRSA in 25 (24%). The 
majority of patients also received concomitant antibiotics 
however (54%), reflecting the potential polymicrobial nature 
of these infections.
Overall success (cured or improved) was observed in 
91.3% with SSI and no statistical difference was observed 
between pathogens except for the small number of infections 
caused by vancomycin-resistant Enterococcus species, where 
success was observed in 5/8 (63%). On logistic regression 
vancomycin-resistant enterococcal infection was found to 
be an independent risk factor for failure (odds ratio 14.2, 
95% confidence interval 1.3–154). This observation in a 
small number of patients has not been reflected in large 
  international surveillance programmes.49–54
Diabetic foot infections
Pharmacokinetic data have shown that daptomycin effec-
tively penetrates the soft tissue and bone in patients with 
diabetic foot infections.24 The clinical evidence supporting 
daptomycin use in diabetic foot ulcers (DFUs) largely comes 
from a subset analysis of the two international Phase III 
RCTs previously discussed.55 In these studies, 133 patients 
(12% of the total) had DFU infection and 103 were clinically 
evaluable. 47 received daptomycin and 56 received either 
vancomycin or semi-synthetic penicillin. Most infections 
were monomicrobial and S. aureus was the predominant 
pathogen, with MRSA isolated in 18.2%. There were no sta-
tistically significant differences between the daptomycin and 
the comparator groups for either the overall clinical outcomes 
(66% versus 70% respectively) or when analysed by infecting 
organism.55 Of the 39 patients treated for DFUs in CORE 
2004, 35 (90%) were successful (cured or improved).15
Daptomycin in outpatient 
management of cSSTI
Outpatient parenteral antibiotic therapy (OPAT) is increasingly 
recognized as a cost-effective management option for patients 
with SSTIs where the appropriate guidance and expertise are 
available.30 OPAT enables shorter length of hospital stay or 
even avoidance of admission in appropriate patients, confer-
ring patient convenience, a significant reduction in hospital 
costs,56 and also reduced risk of health care associated infec-
tion. However, a recent study in Glasgow, where OPAT is well 
established, shows that the service remains poorly accessed in 
patients with MRSA-associated SSTIs with only 10 (5.8%) 
of 173 patients receiving OPAT over a 16 month period and 
potentially one third of survivors having had the potential to 
be discharged earlier with either oral therapy or OPAT.57
In the UK for OPAT-managed SSTIs when MRSA is 
not suspected and there is no history of beta lactam allergy, 
Ceftriaxone 1–2 g IV daily is the standard of care.58 In sus-
pected MRSA or allergy, teicoplanin is the usual alternative 
pending IV to oral switch. Current recommendations are 
for teicoplanin to be administered via a loading regimen 
of three 400 mg doses 12 hourly followed by daily dosing. 
As the loading regimen is most easily performed in hospital Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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the opportunity for an avoided admission may be lost. Also 
higher doses (600–800 mg/day) of teicoplanin are generally 
preferred by most UK infection specialists. In some centers 
higher doses of teicoplanin (10–15 mg/kg) are used with a 
daily loading regimen for 3 days followed by thrice weekly 
dosing until oral switch is feasible.59 In a recently reported 
cohort of nearly 1000 OPAT-managed SSTIs (approximately 
150 of whom received teicoplanin as per the above regimen), 
first line OPAT therapy with teicoplanin was identified as an 
independent risk factor for OPAT failure (as defined by either 
intolerance/allergy, progression of infection or readmission). 
Increased rates of failure were largely due to teicoplanin 
intolerance or allergy. Increased duration of therapy com-
pared to ceftriaxone treated patients may have reflected the 
intermittent dosing regimen.60
Daptomycin is well suited to OPAT use. It has proven 
clinical efficacy in cSSTIs and a low and predictable 
toxicity profile. A half-life of 8–9 hours and a prolonged 
post-  antibiotic effect (.6 hours), allows once-daily IV 
bolus administration. There is growing clinical experience 
  supporting daptomycin’s use in the OPAT setting.
In CORE 2005, 539 (56.8%) of the clinically evaluable 
patients received OPAT, either de novo or following inpa-
tient initiation.56 One hundred and seventy seven (32.8%) 
OPAT treated patients had cSSTI. Proportionally more 
uncomplicated SSTIs were managed via OPAT (18.4% 
versus 8.8% managed solely via inpatient antibiotic therapy 
[IPAT], P , 0.001). cSSTI rates were similar in OPAT 
and IPAT groups. Cure or improvement was observed in 
94.6% OPAT treated patients versus 86.3% for those treated 
with IPAT alone (chi-squared test ,0.001). OPAT was 
also associated with fewer adverse events, reflecting patient 
  selection for OPAT versus IPAT.
Within EU-CORE between 2006 and 2008,61 153 (13.6%) 
received daptomycin via OPAT. Thirty four patients (22.1%) 
were treated for cSSTIs. Overall in OPAT 58 (37.9%) of 
infections were due to S. aureus, the majority of which were 
MRSA. Daptomycin was typically administered at 4 mg/kg 
(n = 55, 35.9%) and 6 mg/kg (n = 79, 51.6%) and clinical suc-
cess at 30 days post-treatment was observed in 136 (88.9%). 
Possible adverse events were reported in 16 patients, but all 
were mild to moderate in severity.
Future developments and areas  
of controversy
Daptomycin resistance
Daptomycin resistance is rare, with more than 99% suscep-
tibility of Gram-positive isolates in recent large European, 
North and South American, as well as Australian and 
New Zealand surveillance studies, including amongst MRSA 
and vancomycin resistant enterococci (VRE).49–54 To our 
knowledge resistance has not been reported in patients with 
SSTIs, but there are several case reports of daptomycin non-
susceptibility and/or resistance emerging during treatment in 
patients with deep-seated infections, highlighting the key role 
that surgical debridement has in these circumstances.27,62,63
Although some in vitro data have led to concerns regard-
ing increased risk of daptomycin resistance associated with 
intermediate susceptibility to vancomycin (VISA),64,65 recent 
clinical data have shown that in the vast majority of cases of 
VISA, daptomycin remained effective.66 Animal data have 
shown that increasing the dose of daptomycin can improve 
its efficacy for S. aureus strains with reduced daptomycin 
susceptibility,67 therefore using a higher dose may be advis-
able in these patients until evidence is available to guide 
management.
Dosing of daptomycin in SSTIs
The current licensed dosing for SSTIs is 4 mg/kg in SSTIs15 
and 6 mg/kg in bacteremia.27 There are recent data supporting 
the safe use of daptomycin at doses up to 12 mg/kg, including 
in patients with a CrCl of , 30 mL /minute and on hemo-
dialysis, when dosing interval is appropriately adjusted.67,68 
Furthermore, the presence of bacteremia, endocarditis, severe 
renal dysfunction (defined as an initial CrCl , 30 mL/  minute)   
and diabetes mellitus were the variables independently 
associated with clinical failure of daptomycin therapy.46 
Therefore, although the 4 mg/kg dose has been shown to be 
effective and is appropriate for the majority of patients with 
SSTIs, it has been suggested that higher dosing at 6 mg/kg 
should be considered in certain patient groups (Table 6).30 
In particular this includes patients at risk of, or proven to have 
bacteremia, which should include those presenting with a sep-
sis syndrome or requiring high dependency or intensive care 
Table  6  Patients  with  SSTI  in  whom  initial  daptomycin  dose 
should be $6 mg/kg
Associated sepsis syndrome 
Otherwise suspected or confirmed bacteremia or endocarditis
Diabetic foot infection/infected ulcer
Suspected underlying osteomyelitis or septic arthritis
Intravenous drug user
Burns injurya 
Glycopeptide intermediate-resistant MRSA
Consider when creatinine clearance ,30 mL/minuteb
Note:  aConsider doses of 10–12 mg/kg;  bDosing interval should be increased to 
48 hourly.
Abbreviation: MRSA, methicillin resistant Staphylococcus aureus.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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due to cSSTI. In diabetic patients with a SSTI   complicating 
a foot ulcer, the possibility of an osteoarticular infection can 
be difficult to exclude initially, and therefore higher doses 
would be advisable in these patients.69 Patient groups at risk 
of SSTIs who are known to have altered drug pharmacokinet-
ics are also likely to require higher doses. Intravenous drug 
users (IVDU) have increased drug clearance and are therefore 
likely to require the 6 mg/kg dose, although clinical data are 
not yet available to confirm this.27 Another group is patients 
with burn injuries. In 2008 a pharmacokinetic study looked 
at nine patients with $18% body surface area burns between 
7 and 27 days after the burn injury. They demonstrated a 
decreased area under the curve (AUC), increased volume 
of distribution and more rapid clearance of daptomycin 
(as is seen with other antibiotics evaluated in burns patients) 
compared to normal controls. This is felt to reflect clearance 
of daptomycin through the burn wound itself. The AUC was 
reduced by 47% for burns patients with a 6 mg/kg dose, and 
as its pharmacokinetics are linear, the authors suggest that 
a dose of 10–12 mg/kg would be required in this group of 
patients to achieve similar drug exposures to those achieved 
in healthy volunteers.70
economics
Drug acquisition costs have been one of the major hurdles 
in daptomycin becoming a first line treatment option in 
countries where health care is state funded. However, in 
a recent Canadian review of cost drivers associated with 
MRSA infection, antimicrobial therapy only made up 4% of 
the total cost, while hospitalization was estimated to be by 
far the largest driver (at 81% of the cost per patient).71 The 
authors estimated that direct health care cost attributable to 
MRSA in Canada averaged $82 million in 2004 and could 
reach $129 million in 2010.
Daptomycin is highly suitable as an empirical parenteral 
antibiotic option in patients with cSSTI to enable OPAT, 
particularly when there is a suspicion of MRSA infection or 
serious beta lactam allergy. More rapid hospital discharge 
or admission avoidance for patients with SSTI in whom IV 
therapy is indicated, gives a distinct economic advantage. 
A study in Ohio reviewed outcomes of the first 50 con-
secutive patients treated with daptomycin in a community 
hospital, 31 of whom had cSSTI.72 Out of the 50 patients, 
31 (62%) had confirmed MRSA infection. Fourteen patients 
(28%) transitioned to outpatient daptomycin therapy saving 
an estimated $102,340 in hospital charges. In 48 (96%), 
infection resolved with daptomycin therapy. Although this 
study was limited by its observational retrospective nature, 
it   emphasises the significant cost savings that accompany 
shorter or no hospitalization in these patients.
Shorter duration of therapy could confer economic 
  advantage, however to date the in vitro rapid cidality of 
daptomycin has yet to be translated into a demonstrably more 
rapid clinical response or shorter therapy duration.
More clinical and economic data are required to fully 
evaluate daptomycin’s cost efficiency in comparison to the 
glycopeptides and to linezolid. Particularly important ques-
tions are whether daptomycin use can achieve quicker clinical 
improvement and hence shorter course IV therapy in both 
hospital and OPAT settings compared to the glycopeptides 
or linezolid and whether this, combined with OPAT use, can 
translate to shorter hospitalization. To date these questions 
have not been addressed in clinical trials.
Current international 
recommendations
The current international guidelines for the management 
of SSTIs in patients known to have, or at risk of MRSA are 
summarized in Table 7. Daptomycin is considered a first 
line option for cSSTIs in the UK14,73 and the USA26 and 
second line in severe infections in Spain.74 Daptomycin is 
recommended as one of the options for enabling OPAT in 
the UK.73
Summary and recommendations
SSTIs form a substantial part of acute hospital care in all 
countries. Infections with MRSA, the presence of beta lactam 
allergy and declining efficacy of the glycopeptides requires 
that alternative antibiotics are available. For inpatients at risk 
of MRSA or with beta lactam allergy, glycopeptides are likely 
to remain the first line option in the majority of patients at 
present. The data presented to date have not demonstrated 
superiority of daptomycin over glycopeptides in cSSTI, 
however daptomycin is likely to remain an important second 
line agent in those failing or intolerant of the glycopeptides. 
If in vitro rapid cidality data translates to a more rapid clini-
cal improvement in future studies, the significant benefits 
of shorter course therapy and shorter hospitalization could 
encourage greater empirical use of daptomycin in cSSTI in 
hospital. As clinicians become more experienced with the 
use of OPAT to manage SSTI, and aware of the substantial 
economic and psychosocial benefits derived from non-
inpatient management, daptomycin may become increas-
ingly used, particularly in patients at risk of infection with 
resistant Gram-positive pathogens. A proposed algorithm for 
  management of cSSTI is shown in Figure 1.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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Table 7 Current international MRSA SSTI guidelines
Guideline 1st line Alternative OPAT IVOST Duration
Spain74
SSTI (mild) Clindamycin
Doxycycline
Co-trimoxazole NA NA No comment
SSTI (more severe) Linezolid, vancomycin ± 
Clindamycin
Tigecycline (polymicrobial)
Daptomycin (MIC $ 1.5)
No comment Linezolid No comment
UK14,73
SSTI (non-hospital) Doxycycline Clindamycin
Rifampicin + (Fusidate or 
Doxycycline or Trimethoprim)
Linezolid
Co-trimoxazole
Glycopeptide
Daptomycin
Yes No comment
SSTI (hospital) Glycopeptide
Linezolid
Daptomycin
Tigecycline (polymicrobial)
Clindamycin
Glycopeptide
Daptomycin
Clindamycin
Linezolid
No comment
USA26
uSSTI Clindamycin
TMP-SMX
Tetracycline
Linezolid
No comment Not applicable Not applicable 5–10 days
cSSTI vancomycin
Linezolid
Daptomycin
Telavancin
Clindamycin
No comment No comment Linezolid
Clindamycin
7–14 days
Abbreviations: NA, Not applicable; OPAT, Outpatient parenteral antibiotic therapy; IvOST, Intravenous to Oral antibiotic Switch Therapy; SSTI, skin and soft tissue 
infection; uSSTI, uncomplicated SSTI; cSSTI, complicated SSTI.
cSSTI
Skin/soft tissue infection involving deep soft tissue or requiring
surgical intervention, or with significant underlying co-morbidity
At risk of MRSA (table 1)
or significant beta lactam
allergy?
Suitable for OPAT? 
•  Stable comorbidity 
•  Not rapidly progressive 
•  SIRS <2
Yes 
No
Treat with Penicillinase-
resistant penicillin and add
clindamycin if severe
and
Consider IVOST
Yes
IPAT
Vancomycin IV
or
Daptomycin IV
 or
Linezolid po
OPAT 
Daptomycin IV
or
Teicoplanin IV
No
Consider
• Additional Gram-negative
cover
• Addition of Clindamycin if 
cSSTI rapidly progressive
IVOST 
Review IV daily and switch when significant 
reduction in heat, erythema, tenderness
Review potential agents with culture results
Total therapy duration 7–14 days depending
on clinical response 
Consider OPAT with
Ceftriaxone if requiring IV therapy
but suitable for ambulatory care
and
Consider IVOST
Figure 1 Proposed antibiotic management algorithm for MRSA cSSTIs.
Abbreviations: OPAT, Outpatient parenteral antibiotic therapy; IPAT, Inpatient parenteral antibiotic therapy; IvOST, Intravenous to oral antibiotic switch therapy.Infection and Drug Resistance 2011:4 submit your manuscript | www.dovepress.com
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